MGC Pharmaceuticals Limited Results of Shareholder's General Meeting (2986R)
25 10월 2023 - 11:16PM
UK Regulatory
TIDMMXC
RNS Number : 2986R
MGC Pharmaceuticals Limited
25 October 2023
MGC Pharmaceuticals Ltd.
Results of Shareholder's General Meeting
25 October 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would
like to announce the voting results from the Company's General
Meeting of shareholders, held today Wednesday, 25 October 2023.
The Company advises that all motions put to the meeting were
voted by poll, with all resolutions carried.
Details of the results can be found in the following URL:
https://www.investi.com.au/api/announcements/mxc/a32848fb-715.pdf
As a result of Resolution 1 having been passed at the General
Meeting, shareholders have approved the reduction in the number of
ordinary shares by way of a consolidation on the basis of 1,000
ordinary shares into one new ordinary share (' New Ordinary Share
') (collectively, the ' Consolidation ').
For Depositary Interests (' DIs '), which represent ordinary
shares of the Company (' Shares '), and which are traded on the
Main Market of London Stock Exchange plc, the proposed timetable
for the DI consolidation will be as follows:
Shareholders' Approval Granted to Proceed with Consolidation 25 October
of Capital 2023
Last Day Trading in Existing Dis, Representing Unconsolidated 27 October
Shares 2023
-----------
Suspension Of Admission to Trading on London Stock 30 October
Exchange (7.30am) 2023
-----------
Consolidation record date 31 October
2023
-----------
Ex Date and Restoration of Dealings in the DIs, 2 November
now Representing Consolidated Shares, on London 2023
Stock Exchange on Existing ISIN (AU000000MXC6)
-----------
CREST Accounts Credited with dis Now Representing 2 November
Revised Number of Consolidated Shares 2023
-----------
To avoid market confusion and potentially unsettled trades at
the Record date, trading in the Company's DIs on the Main Market of
London Stock Exchange plc will be suspended at 7.30am on 30 October
2023, and restored to trading at 7:30am 2 November 2023.
An application will be made for 3,067,544 New Ordinary Shares
(representing the pre-consolidation number of Shares currently
admitted and trading) to be admitted to the Financial Conduct
Authority's Official List and to trading on the Main Market of
London Stock Exchange plc. Dealings in the consolidated Shares are
expected to commence on 2 November 2023 under the existing ISIN
AU000000MXC6.
Following the issuance of the New Ordinary Shares, the Company
will have 4,427,969 Shares in issue, each with one voting right.
Therefore, the Company ' s total number of Shares in issue and
voting rights will be 4,427,969 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA ' s
Disclosure Guidance and Transparency Rules.
- Ends-
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6555 2950 +61 8 6555 2950
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK IR/PR Advisers UK Brokers
IFC Advisory Oberon Capital
Graham Herring / Tim Metcalfe / Aimee McCusker / Adam Pollock
Zach Cohen +44 203 179 5300
+44 203 934 6630 aimeemccusker@oberoninvestments.com
mgcpharma@investor-focus.co.uk adampollock@oberoninvestments.com
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant inspired medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMMABITMTBTBIJ
(END) Dow Jones Newswires
October 25, 2023 10:16 ET (14:16 GMT)
Mgc Pharmaceuticals (LSE:MXC)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Mgc Pharmaceuticals (LSE:MXC)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
